Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Provided By PR Newswire
Last update: Mar 31, 2025
The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70
Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025
Read more at prnewswire.comNASDAQ:TLPH (9/30/2025, 8:00:01 PM)
0.8932
-0.02 (-1.85%)
Find more stocks in the Stock Screener
